文献速递复苏、休克与脓毒症创伤与烧伤重症综合管理与镇静镇痛

三因子与四因子凝血酶原复合物在猪失血性休克模型中的「基于因子」复苏比较

Three- versus four-factor prothrombin complex concentrates for "factor-based" resuscitation in a porcine hemorrhagic shock model.
PubMed 文献 · J Trauma Acute Care Surg · 2017-01-01
一句话结论猪失血性休克模型中,凝血酶原复合物未能纠正凝血障碍并消耗纤维蛋白原和血小板,3因子产品较4因子产品更易导致消耗性凝血病,作者建议此情境下慎用。

该研究在25头成年约克夏猪中建立35%失血量、缺血再灌注损伤及程序化晶体液复苏的严重失血性休克与凝血障碍模型,17头在造模后4小时随机接受45 IU/kg的3因子或4因子凝血酶原复合物,另8头在4因子凝血酶原复合物前接受自体血浆输注。模型造成显著酸中毒(平均pH 7.21,乳酸9.6 mmol/L)。给药后3因子组66.7%、4因子组25%发生消耗性凝血病;发生消耗性凝血病者呈现「致死三联征」:体温更低(36.3°C vs 37.8°C)、酸中毒更重(pH 7.14 vs 7.27;碱剩余-12.1 vs -6.5 mEq/L)、凝血障碍更差(凝血酶原时间17.1 vs 14.6秒;纤维蛋白原87.9 vs 124.1 mg/dL)(均p<0.05)。无消耗性凝血病时,两药可改善个别凝血因子并短暂改善凝血酶原时间,但纤维蛋白原和血小板显著消耗且凝血障碍无持久改善。作者认为凝血酶原复合物未能纠正凝血障碍并与纤维蛋白原和血小板消耗相关,更令人担忧的是在病情更重的动物中导致消耗性凝血病,3因子产品发生率明显高于4因子产品,此情境下应慎用。

要点

  • 猪严重失血性休克与凝血障碍模型中,给予45 IU/kg凝血酶原复合物后3因子组66.7%、4因子组25%发生消耗性凝血病。
  • 发生消耗性凝血病者呈现致死三联征:体温36.3°C vs 37.8°C、pH 7.14 vs 7.27、碱剩余-12.1 vs -6.5 mEq/L(均p<0.05)。
  • 发生消耗性凝血病者凝血障碍更差:凝血酶原时间17.1 vs 14.6秒、纤维蛋白原87.9 vs 124.1 mg/dL(均p<0.05)。
  • 无消耗性凝血病时,两药仅短暂改善凝血酶原时间,纤维蛋白原和血小板显著消耗,凝血障碍无持久改善。
  • 作者认为凝血酶原复合物在此情境下应慎用,3因子产品消耗性凝血病发生率明显高于4因子产品。

适用人群与场景

  • 成年约克夏猪,经历35%失血量、缺血再灌注损伤及程序化晶体液复苏的严重失血性休克与凝血障碍模型。
  • 17头在造模后4小时随机接受3因子或4因子凝血酶原复合物;另8头在4因子凝血酶原复合物前接受自体血浆输注。

处置流程与药物剂量

  • 造模后4小时给予45 IU/kg剂量的3因子或4因子凝血酶原复合物(猪模型,非临床推荐剂量)。
  • 部分动物在4因子凝血酶原复合物前接受自体血浆输注。
  • 在4小时和6小时抽取个别凝血因子水平。

红旗征与不能漏的情况

  • 发生消耗性凝血病者呈现致死三联征:体温更低(36.3°C vs 37.8°C)、酸中毒更重(pH 7.14 vs 7.27;碱剩余-12.1 vs -6.5 mEq/L)、凝血障碍更差(凝血酶原时间17.1 vs 14.6秒;纤维蛋白原87.9 vs 124.1 mg/dL)(均p<0.05)。

研究设计与关键结果

  • 研究类型:猪严重失血性休克与凝血障碍模型的随机对照实验;25头成年约克夏猪,17头随机接受3因子或4因子凝血酶原复合物,另8头在4因子凝血酶原复合物前接受自体血浆。
  • 模型造成显著酸中毒:平均pH 7.21,乳酸9.6 mmol/L。
  • 给药后消耗性凝血病发生率:3因子组66.7%,4因子组25%(无论是否输注血浆)。
  • 发生消耗性凝血病者呈现致死三联征:体温36.3°C vs 37.8°C、pH 7.14 vs 7.27、碱剩余-12.1 vs -6.5 mEq/L、凝血酶原时间17.1 vs 14.6秒、纤维蛋白原87.9 vs 124.1 mg/dL(均p<0.05)。
  • 无消耗性凝血病时,3因子和4因子凝血酶原复合物改善个别凝血因子并短暂改善凝血酶原时间,但纤维蛋白原和血小板显著消耗,凝血障碍无持久改善。

证据类型、等级与局限

  • 证据类型:动物实验(猪模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为凝血酶原复合物未能纠正凝血障碍并与纤维蛋白原和血小板消耗相关。
  • 作者认为在病情更重的动物中凝血酶原复合物导致消耗性凝血病,3因子产品发生率明显高于4因子产品,这些产品在此情境下应慎用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Bleeding is a leading cause of preventable death after severe injury. Prothrombin complex concentrates (PCC) treat inborn coagulation disorders and reverse oral anticoagulants, but are proposed for use in "factor-based" resuscitation strategies. Few studies exist for this indication in acidosis, or that compare 3-factor PCC (3PCC) versus 4-factor PCC (4PCC) products. We aimed to assess and compare their safety and efficacy in a porcine model of severe hemorrhagic shock and coagulopathy.

METHODS: Twenty-five adult Yorkshire swine underwent 35% volume hemorrhage, ischemia-reperfusion injury, and protocolized crystalloid resuscitation. Seventeen animals were randomized at 4 hours after model creation to receive a 45-IU/kg dose of either 3PCC or 4PCC. An additional eight animals received autologous plasma transfusion before 4PCC to better characterize response to PCC. Individual factor levels were drawn at 4 hours and 6 hours.

RESULTS: The model created significant acidosis with mean pH of 7.21 and lactate of 9.6 mmol/L. After PCC, 66.7% of 3PCC animals and 25% of 4PCC animals (regardless of plasma administration) developed consumptive coagulopathy. The animals that developed consumptive coagulopathy had manifested the "lethal triad" with lower temperatures (36.3°C vs. 37.8°C), increased acidosis (pH, 7.14 vs. 7.27; base excess, -12.1 vs. -6.5 mEq/L), and worse coagulopathy (prothrombin time, 17.1 vs. 14.6 seconds; fibrinogen, 87.9 vs. 124.1 mg/dL) (all p < 0.05). In the absence of a consumptive coagulopathy, 3PCC and 4PCC improved individual clotting factors with transient improvement of prothrombin time, but there was significant depletion of fibrinogen and platelets with no lasting improvement of coagulopathy.

CONCLUSION: PCC failed to correct coagulopathy and was associated with fibrinogen and platelet depletion. Of greater concern, PCC administration resulted in consumptive coagulopathy in the more severely ill animals. The incidence of consumptive coagulopathy was markedly increased with 3PCC versus 4PCC, and these products should be used with caution in this setting.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Moe DM, Lallemand MS, McClellan JM, et al. Three- versus four-factor prothrombin complex concentrates for "factor-based" resuscitation in a porcine hemorrhagic shock model. J Trauma Acute Care Surg. 2017. PMID: 28700408. doi:10.1097/TA.0000000000001646

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。